[Hardly any hypoglycemias, constant weight--and still cost effective].
D001835:Body Weight; D003362:Cost-Benefit Analysis; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy*; D016568:Drugs, Generic / Q000009:adverse effects* / Q000191:economics / Q000627:therapeutic use; D005905:Glyburide / Q000009:adverse effects* / Q000627:therapeutic use; D006801:Humans; D007003:Hypoglycemia / Q000139:chemically induced*; D007004:Hypoglycemic Agents / Q000009:adverse effects* / Q000191:economics / Q000627:therapeutic use; D007333:Insulin Resistance; D013453:Sulfonylurea Compounds / Q000009:adverse effects* / Q000191:economics / Q000627:therapeutic use
D016568:Drugs, Generic; D007004:Hypoglycemic Agents; D013453:Sulfonylurea Compounds; C057619:glimepiride; D005905:Glyburide